Are intranasal steroids effective in minimizing utilization of antibiotics for acute rhinosinusitis?
A randomized placebo-controlled trial demonstrated that mometasone furoate nasal spray 200 mcg twice daily significantly enhanced minimal symptom days versus amoxicillin or placebo in rhinosinusitis patients aged 12 years and older. This benefit was noted within 2 days and allowed patients to return to activity earlier. The results are promising that inhaled corticosteroid therapy can enhance outcome in rhinosinusitis; while minimizing inappropriate antibiotic use.
Meltzer EO, Gates D, Bachert C, et al: Mometasonefuroate nasal spray increases the number of minimalsymptom days in patients with acute rhinosinusitis.Ann Allergy Asthma Immunol. 2012;108:275-279.